Literature DB >> 20479661

Comparative effectiveness research: what kind of studies do we need?

John Concato1, Peter Peduzzi, Grant D Huang, Timothy J O'Leary, Joel Kupersmith.   

Abstract

Comparative effectiveness research (CER) is increasingly popular, yet discussions of its conduct and consequences often overlook the extensive history of comparing different therapeutic options in patient-oriented research. In particular, research in the Department of Veterans Affairs (VA) has included a decades-long focus on generating information that can enhance medical decision making and improve health outcomes. Categories of such research include multisite randomized controlled trials (conducted by the Cooperative Studies Program) and observational studies involving either primary or secondary data collection. As representative examples from cardiology, a landmark VA clinical trial published in the 1970s evaluated the benefits of coronary artery bypass grafting surgery among patients with angina; a VA trial initiated in the 1990s, and identified formally as CER, demonstrated that percutaneous coronary intervention is not superior to optimal medical therapy; and a database investigation using information from the VA electronic medical record system in the 2000s found that use of proton pump inhibitor medication is associated with the attenuation of the benefits of clopidogrel among patients hospitalized for acute coronary syndrome. A review of these (and other) selected projects, based on their type of study design, serves to highlight the strengths, limitations, and potential of CER.

Entities:  

Mesh:

Year:  2010        PMID: 20479661     DOI: 10.231/JIM.0b013e3181e3d2af

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  11 in total

1.  Point-of-Care Clinical Trials in Sports Medicine Research: Identifying Effective Treatment Interventions Through Comparative Effectiveness Research.

Authors:  Kenneth C Lam; Cailee E Welch Bacon; Eric L Sauers; R Curtis Bay
Journal:  J Athl Train       Date:  2019-10-16       Impact factor: 2.860

2.  The Trials and Tribulations of Selecting Comparison Groups in Randomized Trials of Nonpharmacological Complementary and Integrative Health Interventions.

Authors:  Karen J Sherman
Journal:  J Altern Complement Med       Date:  2020-03-11       Impact factor: 2.579

3.  Preference option randomized design (PORD) for comparative effectiveness research: Statistical power for testing comparative effect, preference effect, selection effect, intent-to-treat effect, and overall effect.

Authors:  Moonseong Heo; Paul Meissner; Alain H Litwin; Julia H Arnsten; M Diane McKee; Alison Karasz; Paula McKinley; Colin D Rehm; Earle C Chambers; Ming-Chin Yeh; Judith Wylie-Rosett
Journal:  Stat Methods Med Res       Date:  2017-11-09       Impact factor: 3.021

4.  Uses and misuses of statistics: the case of strontium ranelate and the number needed to treat.

Authors:  M Pedrazzoni; A Giusti; G Pioli
Journal:  J Endocrinol Invest       Date:  2011-09       Impact factor: 4.256

5.  The missing link in preconceptional care: the role of comparative effectiveness research.

Authors:  Hamisu M Salihu; Abraham Salinas; Mulubrhan Mogos
Journal:  Matern Child Health J       Date:  2013-07

Review 6.  Pharmacologic Neuroprotection for Functional Outcomes After Traumatic Brain Injury: A Systematic Review of the Clinical Literature.

Authors:  Shaun E Gruenbaum; Alexander Zlotnik; Benjamin F Gruenbaum; Denise Hersey; Federico Bilotta
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

7.  Future directions for cardiovascular disease comparative effectiveness research: report of a workshop sponsored by the National Heart, Lung, and Blood Institute.

Authors:  Mark A Hlatky; Pamela S Douglas; Nakela L Cook; Barbara Wells; Emelia J Benjamin; Kay Dickersin; David C Goff; Alan T Hirsch; Elaine M Hylek; Eric D Peterson; Véronique L Roger; Joseph V Selby; James E Udelson; Michael S Lauer
Journal:  J Am Coll Cardiol       Date:  2012-07-11       Impact factor: 24.094

8.  Comparative effectiveness research on patients with acute ischemic stroke using Markov decision processes.

Authors:  Darong Wu; Yefeng Cai; Jianxiong Cai; Qiuli Liu; Yuanqi Zhao; Jingheng Cai; Min Zhao; Yonghui Huang; Liuer Ye; Yubo Lu; Xianping Guo
Journal:  BMC Med Res Methodol       Date:  2012-03-09       Impact factor: 4.615

Review 9.  Using multiple types of studies in systematic reviews of health care interventions--a systematic review.

Authors:  Frank Peinemann; Doreen Allen Tushabe; Jos Kleijnen
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

10.  Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system.

Authors:  Raymond K Cross; Michael Chiorean; Francis Vekeman; Yongling Xiao; Eric Wu; Jingdong Chao; Anthony W Wang
Journal:  PLoS One       Date:  2019-12-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.